EZH2 mutations, especially hotspot mutations affecting Y641, drive B cell lymphoma development, and EZH2 inhibition is considered an attractive therapeutic option in EZH2-mutated B cell lymphomas, including DLBCL (28, 29). The gene discussed is EZH2; the disease is B-cell non-Hodgkin lymphoma.